Schedule 13G ownership disclosure
CATALYST PHARMACEUTICALS, INC.
Common Stock · CUSIP: 14888U101
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deerfield Mgmt, L.P.
Shares: 3,133,011.00 · Class: 2.63%
- Deerfield Management Company, L.P.
Shares: 3,133,011.00 · Class: 2.63%
- Deerfield Partners, L.P.
Shares: 3,133,011.00 · Class: 2.63%
- James E. Flynn
Shares: 3,133,011.00 · Class: 2.63%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193805-25-000175
- Form type
- SCHEDULE 13G/A
- Filer
- CATALYST PHARMACEUTICALS, INC.
- CIK
- CIK 1369568
- Filed
- Feb 13, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership